Fast Pharmacology: SERT Is Blocked Almost Immediately
Placeholder: SERT blockade is fast; feeling better is not.
- Hours: SERT blockade onset (placeholder timing)
- Rapid: Synaptic 5-HT rise (placeholder curve)
- ~0%: Felt relief so far (placeholder gap)
- ~1 day: Drug half-life (placeholder, agent-dependent)
What actually happens on day one
Placeholder: transporter blocked, serotonin climbs, mood unchanged yet.
Why this is only the first step
Placeholder: occupancy is not the same thing as clinical response.
Placeholder: fast target engagement, slow felt benefit.
The Autoreceptor Brake — Why Early Days Can Feel Worse
Placeholder: 5-HT1A autoreceptors push back against the extra serotonin.
- Inhibitory: Autoreceptor response (placeholder feedback)
- Minimal: Typical felt benefit (placeholder window)
- Possible: Activation-type effects (placeholder side effects)
- ~1–2 wk: Duration of this phase (placeholder estimate)
Negative feedback slows net signaling
Placeholder: raphe firing rate drops, offsetting reuptake blockade.
Why patients may feel more anxious first
Placeholder: early activation syndrome, not a sign of failure.
Placeholder: worse-before-better is pharmacologically expected here.
The Brake Releases — Autoreceptors Desensitize
Placeholder: over weeks, inhibitory autoreceptors lose sensitivity.
- 2–4 wk: Desensitization window (placeholder estimate)
- Rising: Net serotonergic tone (placeholder trend)
- Emerging: Clinical signal (placeholder, partial)
- Receptor adaptation: Mechanism type (placeholder label)
From braked to disinhibited signaling
Placeholder: firing rate normalizes, forebrain serotonin output climbs.
First hints of symptom change
Placeholder: small, inconsistent improvement often starts here.
Placeholder: this is the pivot point of the whole delay.
Downstream Neuroplasticity Accumulates
Placeholder: BDNF signaling and synaptic remodeling build up.
- Upregulated: BDNF/TrkB signaling (placeholder pathway)
- Weeks-long: Dendritic remodeling (placeholder timescale)
- Gene transcription: Requires (placeholder mechanism)
- Accelerating: Improvement trend (placeholder trajectory)
Structural change, not just chemistry
Placeholder: spine growth and synaptogenesis take real time.
Why this cannot be rushed
Placeholder: protein synthesis and rewiring are inherently slow.
Placeholder: this is the biological floor on how fast SSRIs can work.
Why Staying the Course Through the Gap Matters
Placeholder: benefit lands around week 4–6 if treatment continues.
- Wk 4–6: Typical benefit onset (placeholder window)
- Benefit stalls: Risk if stopped early (placeholder outcome)
- 4–6 wk: Recommended trial length (placeholder guidance)
- Common: Premature stop rate (placeholder note)
What continuing through the gap buys
Placeholder: adherence lets desensitization and plasticity finish.
What stopping early costs
Placeholder: the model above resets before benefit consolidates.
Placeholder: the gap is expected, not evidence the drug failed.